Santosh Varalwar, MD, Vivimed Labs
HYDERABAD, INDIA: Vivimed Labs Ltd has acquired Uquifa, a Spanish pharma company for $55 million.
Under the current deal, Uquifa gets the supply side efficiencies and knowledge base of Vivimed while Vivimed would leverage the pre-eminent position of Uquifa and also its robust pipeline of filings to accelerate growth across Europe and the Americas in the next five years.
“In a move to bring in strategic growth into its product mix and expand the footprint in Europe and the Americas, Vivimed Labs has taken a measured stride with the acquisition of Uquifa Spain and Uquifa Mexico,” the company stated.
Uquifa is the pharmaceutical division of UK-based Yule Catto Plc. and operates three manufacturing units – two in Spain and one in Mexico.
Vivimed is engaged in the specialty chemicals and pharmaceuticals businesses in India. The company’s specialty chemicals segment provides active ingredients to manufacturers of beauty care products, industrial care products and photographic chemicals for photo imaging technology. The company also does contract manufacturing and job works for various pharma products.
“Multi-geographical locations spell stability and cement long-term relationships with customers and channel partners. With Uquifa, Vivimed will have a footprint into LATAM and deeper into Europe.” Said Santosh Varalwar, MD, Vivimed Labs.
Post-acquisition, Varalwar will be the president of Uquifa while Mark I Robbins will remain the chief executive. Sandeep Varalwar, head of the pharmaceutical division of Vivimed Labs will also join the board of Uquifa.
© WOC News